R. Whittington

发表

Decision support system for treatment selection: Application of a statistical expert advisor to the problem of prostate cancer treatment selection

M. Altschuler, R. Whittington, 1993 .

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.

A. Renshaw, A. D'Amico, Ming-Hui Chen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer

A. Renshaw, A. D'Amico, I. Kaplan, 1998 .

Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA

A. D'Amico, M. Schnall, S. Malkowicz, 2003, International Journal of Radiation Oncology, Biology, Physics.

Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer

S B Malkowicz, A. Renshaw, A. D'Amico, 2000 .

Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer

S B Malkowicz, A G Yodh, T. Zhu, 2006, Lasers in surgery and medicine.

Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.

D. Neuberg, A. Benson, D. Haller, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer

A. D'Amico, D. Schultz, M. Schnall, 1995 .

Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.

A. D'Amico, D. Schultz, M. Schnall, 1997, Urology.

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.

P. Catalano, J. Berlin, A. Benson, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacologic erection with intracavernosal injection for men with sexual dysfunction following irradiation: a preliminary report.

A. Wein, P. Hanno, R. Whittington, 1991, International journal of radiation oncology, biology, physics.

Radical prostatectomy for high-grade prostate cancer.

A. D'Amico, J. Richie, D. Schultz, 2006, Urology.

Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.

A. D'Amico, D. Schultz, I. Kaplan, 2000, Molecular urology.

Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204

A. Benson, Steven J. Cohen, E. Sigurdson, 2013, Cancer.

Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Rese

A. Benson, Steven J. Cohen, E. Sigurdson, 2015, The oncologist.

A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.

D. Schultz, M. Schnall, A. Wein, 1994, International journal of radiation oncology, biology, physics.

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

S. Kalnicki, J. Palefsky, A. Onitilo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.

A. Renshaw, A. D'Amico, J. Richie, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.

T. Guzzo, S. Malkowicz, R. Whittington, 2008, Urology.

Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.

A. Renshaw, A. D'Amico, J. Richie, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients.

A. D'Amico, D. Schultz, M. Schnall, 1996, The cancer journal from Scientific American.

A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer.

D. Schultz, S. Malkowicz, R. Whittington, 1995, International journal of radiation oncology, biology, physics.

5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer

A. D'Amico, D. Schultz, I. Kaplan, 1998 .

Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.

A. Renshaw, A. D'Amico, J. Richie, 1999, International journal of radiation oncology, biology, physics.

Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.

A. Renshaw, A. D'Amico, J. Richie, 2002, The Journal of urology.

Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296).

P. Catalano, A. Benson, F. Spitz, 2012, Gastrointestinal cancer research : GCR.

Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.

P. Catalano, J. Palefsky, A. Benson, 2012 .

Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate.

C. Langlotz, P. Arger, T. Hyslop, 1997, Urology.

Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy.

A. Renshaw, A. D'Amico, D. Schultz, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of preoperative radiotherapy regimens for bladder carcinoma. The university of Pennsylvania experience

L. Solin, A. Wein, R. Whittington, 1988, Cancer.

Screening asymptomatic, middle-aged men for carcinoma of the prostate: can we all stop shouting out our answer for a minute and think about the question?

R. Whittington, 1999, Medical and pediatric oncology.

Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy.

A. D'Amico, T. Guzzo, A. Wein, 2005, Urology.

Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score ≤ 7

A. D'Amico, D. Schultz, A. Wein, 2000, Cancer.

An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy.

A. Renshaw, A. D'Amico, D. Schultz, 1996, Urology.

Combined hormonal and radiation therapy for lymph node-positive prostate cancer.

A. Wein, R. Whittington, M. Dougherty, 1995, Urology.

Identification of clinically significant prostate cancer by prostate-specific antigen screening.

S Bruce Malkowicz, Zelig Tochner, Richard Whittington, 2004, Archives of internal medicine.

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

John E Tomaszewski, Ming-Hui Chen, Anthony V D'Amico, 2002, Cancer.

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.

S B Malkowicz, A. D'Amico, J. Richie, 2001, The Journal of urology.

Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer

D. Schultz, I. Kaplan, J. Richie, 2000, Prostate Cancer and Prostatic Diseases.

Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.

A. D'Amico, D. Schultz, M. Schnall, 2000, The Journal of urology.

Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer.

A. D'Amico, Ming-Hui Chen, A. Wein, 2000, Urology.

A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.

A. D'Amico, D. Schultz, M. Schnall, 1995, The Journal of urology.

The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.

S B Malkowicz, M Machtay, A. Wein, 1997, International journal of radiation oncology, biology, physics.

The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer.

A. D'Amico, Ming-Hui Chen, A. Wein, 1998, The Journal of urology.

Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.

T. J. Robnett, A. Wein, S. Malkowicz, 2001, International journal of radiation oncology, biology, physics.

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.

P. Catalano, A. Benson, N. Petrelli, 2016 .

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

L. True, R. Whittington, R. Byhardt, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current role of MR imaging in the staging of adenocarcinoma of the prostate.

R E Lenkinski, M D Schnall, H Y Kressel, 1993, Radiology.

Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.

Timothy C Zhu, Theresa M Busch, Andreea Dimofte, 2006, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

Calculated prostate carcinoma volume

A. D'Amico, D. Schultz, S. Malkowicz, 1998, Cancer.

Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT.

A. Wein, S. Malkowicz, G. Kao, 1994, Radiology.

The impact of a delay in initiating radiation therapy on prostate‐specific antigen outcome for patients with clinically localized prostate carcinoma

A. Renshaw, A. D'Amico, D. Schultz, 2005, Cancer.

Erectile dysfunction following minimally invasive treatments for prostate cancer.

A. Wein, S. Malkowicz, R. Whittington, 1996, Urology.

Secondary malignant neoplasms in patients with bladder carcinoma.

L. Solin, A. Wein, G. Hanks, 1992, Urology.

Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials.

A. Renshaw, A. D'Amico, J. Richie, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease.

S B Malkowicz, A. D'Amico, D. Schultz, 1998, Urology.

Outcome based staging for clinically localized adenocarcinoma of the prostate.

A. D'Amico, D. Schultz, A. Wein, 1997, The Journal of urology.

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.

A. D'Amico, I. Kaplan, C. Coleman, 1997, International journal of radiation oncology, biology, physics.

Utilizing P redictions o f E arly P rostate-Specifi c A ntigen Failure t o O ptimize P atient S election f or A djuvant Systemic T herapy T rials

A. Renshaw, A. D'Amico, J. Richie, 2000 .

The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer.

M. Altschuler, A. D'Amico, A. Wein, 1993, Clinical performance and quality health care.

A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer.

A. D'Amico, D. Schultz, A. Wein, 1999, Urology.

Treatment of bladder cancer with interstitial iridium-192 implantation and external beam irradiation.

A. Wein, R. Whittington, J. Tomaszewski, 1988, International journal of radiation oncology, biology, physics.

Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy

A. Renshaw, A. D'Amico, J. Richie, 1998, Cancer.

Erectile function and quality of life after interstitial radiation therapy for prostate cancer

S. Malkowicz, R. Whittington, G. Broderick, 2000, International Journal of Impotence Research.

Optical Properties of Human Prostate at 732 nm Measured In Vivo During Motexafin Lutetium–mediated Photodynamic Therapy¶

Timothy C. Zhu, Jarod C. Finlay, Andreea Dimofte, 2005 .

Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients.

A. D'Amico, A. Wein, W. Hwang, 2005, Urology.

Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity.

A. Wein, S. Malkowicz, R. Whittington, 1999, The cancer journal from Scientific American.

The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.

P. Arger, S. Malkowicz, R. Whittington, 1999, International journal of radiation oncology, biology, physics.

PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level.

A. Renshaw, A. D'Amico, J. Richie, 2005, Urologic oncology.

Using the receiver operating characteristic curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure.

M. Altschuler, A. Wein, S. Malkowicz, 2001, Urology.

Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer.

A. D'Amico, D. Schultz, M. Schnall, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial.

A. D'Amico, D. Schultz, A. Wein, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer

Timothy C. Zhu, Debbie Smith, Jarod C. Finlay, 2004, SPIE BiOS.

A. Wein, S. Chhatre, R. Jayadevappa, 2006, BJU international.

Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.

A. D'Amico, D. Schultz, I. Kaplan, 1997, International journal of radiation oncology, biology, physics.

ROC optimization may improve risk stratification of prostate cancer patients.

M. Altschuler, A. D'Amico, A. Wein, 2001, Urology.

In vivo measurement of fluorescence emission in the human prostate during photodynamic therapy

Jarod C Finlay, Timothy C Zhu, Stephen M Hahn, 2005, SPIE BiOS.

The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.

D. Schultz, M. Schnall, A. Wein, 1995, Cancer.

Development of prostate cancer after pituitary dysfunction: a report of 8 patients.

A. Wein, S. Malkowicz, R. Whittington, 1997, Urology.

Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening.

A. Renshaw, A. D'Amico, J. Richie, 2001, Urology.

The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer

A. D'Amico, D. Schultz, M. Schnall, 1995, Cancer.

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

A. Renshaw, A. D'Amico, I. Kaplan, 1998, JAMA.

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

A. Renshaw, A. D'Amico, J. Richie, 2002, Cancer.

E. Sigurdson, R. Whittington, U. Verma, 2013, Cancer.

Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer: ECOG 3204

A. Benson, E. Sigurdson, R. Whittington, 2009 .

Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.

A. Renshaw, A. D'Amico, J. Richie, 2002, The Journal of urology.

Internet use by patients with prostate cancer undergoing radiotherapy.

P Devine, J. Metz, R. Whittington, 2003, Urology.

A. Wein, S. Chhatre, R. Jayadevappa, 2006, BJU international.

In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy

Jarod C Finlay, Timothy C Zhu, Stephen M Hahn, 2004, SPIE BiOS.

Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.

A. Renshaw, A. D'Amico, D. Schultz, 2004, International journal of radiation oncology, biology, physics.